ライフサイエンスコーパス: age at

1 For height-for-age at 4 y, this difference was equal to 3.70 (95% CI: 0

2 of GM to total cerebral volume declined with age at a slower rate in autistic boys and girls relative

3 tween 2013 and 2017 were eligible (77% men); age at admission was 47 years [interquartile range (IQR)

4 groups were matched for age and gestational age at admission.

5 After adjustment for potential covariates, ages at alcohol initiation (AAIs) of 18.1-29.0 years, 29

6 The mean age at appointment was 42.9 years old.

7 age 9.4 y), classified as early treated (ET; age at ART initiation <=0.5 y, n = 14) or late treated (

8 iation <=0.5 y, n = 14) or late treated (LT; age at ART initiation 1-10 y, n = 6).

9 lation-based cohort studies (1983-2018; mean age at baseline = 46 years; median follow-up, 19 years).

10 up, 462 individuals developed dementia (mean age at baseline = 57.5 +/- 5.9 years, 58% women).

11 19 male) with a mean (+/-standard deviation) age at baseline of 76.60+/-6.65 years and median (interq

12 n and no history of CVD and cancer, the mean age at baseline was 50.9 (SD 10.4) years, and 40.8% were

13 ts from the UK Biobank (55% were women, mean age at baseline, 56 years [SD, 8 years]), 4607 CHD and 3

14 pooled sample included 252 745 women (median age at baseline, 57 years) with 38% self-reporting use o

15 Participants averaged 51.7 years of age at baseline; 60% were male.

16 The effects of age at BCG and time since vaccination were also explored

17 in a cohort of n = 64 preterm infants (mean age at birth = 32.0 weeks), we tested whether cortical a

18 RI) in n = 292 healthy newborn infants (mean age at birth = 39.9 weeks) with regional patterns of gen

19 nates who were at least 34 weeks gestational age at birth and enrolled within 48 h of birth, born to

20 Advanced maternal age at birth can have pronounced consequences for offspr

21 Gestational age at birth is declining, probably because more deliver

22 socioeconomic status, birth weight, maternal age at birth, anisometropia, astigmatism, spherical equi

23 Maternal age at birth, maternal level of education, household inc

24 We estimated LOY as age at menopause (age at blood collection for premenopausal women) minus a

25 p analysis according to age at diagnosis and age at blood draw revealed increased methylation levels

26 l hazards regression, declined steadily with age at BMI assessment, from 1.25 (95% confidence interva

27 in VI or blindness with increasing levels of age at both 5- and 10-year time points (p > 0.05).

28 lating drug dose, and an interaction between age at cancer diagnosis and haematopoietic stem-cell tra

29 Ontario children < 18 years of age at cancer diagnosis between 1987 and 2016 were ident

30 erse mental health included younger maternal age at cancer diagnosis, low socioeconomic status, and r

31 Mean age at cirrhosis evaluation was 62.

32 Age at clinical onset, clinical syndrome and family hist

33 Potential confounding variables; maternal age at conception, maternal education level, parental so

34 The mean (SD) age at DBS implantation was 41.0 (11.4) years, and the f

35 cases with cerebral amyloid angiopathy (mean age at death 73 years, nine males) and three controls (m

36 years, nine males) and three controls (mean age at death 91 years, one male) were included in the st

37 The global average age at death from cervical cancer was 59 years, ranging

38 The mean age at death was 61.4 years (range, 56.6 years in West V

39 y of age at onset and 20% (12-30) of that of age at death was explained by family membership.

40 Age at death was unrelated to residual decline in episod

41 death, and r=0.40 individual and mean family age at death) or the GRN group (r=0.22 individual and pa

42 nd r=0.69 between individual and mean family age at death) than in either the C9orf72 group (r=0.32 i

43 CI 35-62, for age at onset; 61%, 47-73, for age at death), and even more by family membership (66%,

44 6%, 56-75, for age at onset; 74%, 65-82, for age at death).

45 death, and r=0.32 individual and mean family age at death).

46 dels to explore differences in age at onset, age at death, and disease duration between genetic group

47 , we collected data on age at symptom onset, age at death, and disease duration for patients with pat

48 international study of age at symptom onset, age at death, and disease duration in individuals with m

49 age at onset, r=0.22 individual and parental age at death, and r=0.32 individual and mean family age

50 age at onset, r=0.38 individual and parental age at death, and r=0.40 individual and mean family age

51 nset, r=0.58 between individual and parental age at death, and r=0.69 between individual and mean fam

52 to 2017 to calculate annual CHD mortality by age at death, race/ethnicity, and sex.

53 neuropathologic burden was weakly related to age at death; it occurred in only about one-third of par

54 As people live longer, ages at death are becoming more similar.

55 Median age at deep brain stimulation was 11.5 years (range: 4.5

56 two clusters demonstrated lower gestational age at delivery (p = 0.049), increased protein excretion

57 95% of postpartum women (median gestational age at delivery 30 weeks).

58 Estimated age at dental maturation in this fossil hominin compares

59 Case notes were reviewed and data on age at detection and presentation as well as other clini

60 he child did not significantly influence the age at detection or presentation.

61 six clinical parameters (GAD autoantibodies, age at diabetes onset, HbA(1c), BMI, and measures of ins

62 OR: 2.4), glaucoma (P = .04; OR: 4.09), and age at diagnosis (P = .005; OR: 1.02) were independent r

63 posterior probability (PP)=0.989) and older age at diagnosis (PP=0.912).

64 ) and secondary glaucoma groups (47%, median age at diagnosis = 3 years), respectively.

65 12.2 and 12.6 years in the PCG (53%, median age at diagnosis = 5 months) and secondary glaucoma grou

66 Subgroup analysis according to age at diagnosis and age at blood draw revealed increase

67 ds on neurocognitive outcomes, adjusting for age at diagnosis and sex.

68 The age at diagnosis and the gender of the uveal melanoma pa

69 Age at diagnosis correlated significantly with pancreas

70 The mean age at diagnosis decreased after establishment of the It

71 Age at diagnosis increased markedly over time (40+/-14 v

72 ratio of 3.9 and a median (minimum-maximum) age at diagnosis of 62 (18-82) years.

73 sed with glaucoma (9/11, 81.8%), with a mean age at diagnosis of 9.22+/-14.89 years, and all individu

74 Globally, the average age at diagnosis of cervical cancer was 53 years, rangin

75 4% (according to both criteria), and younger age at diagnosis of glaucoma (18-39 years) was predictiv

76 The age at diagnosis of JNCL ranged from 7 to 10 years (mean

77 Age at diagnosis of pineal TRb in patients diagnosed wit

78 rter period than previously assumed, and the age at diagnosis of pineal TRb is independent of the age

79 iagnosis of pineal TRb is independent of the age at diagnosis of retinoblastoma.

80 In the SEER database, the median age at diagnosis of uveal melanomas was 63 (range 3-99 y

81 unique clinical variables such as patients' age at diagnosis or information regarding lymph nodes, w

82 Age at diagnosis varied by sex and genotype despite simi

83 Median age at diagnosis was 1.9 years, median follow-up was 4.0

84 ard deviation (SD), range 0.2-5.0], the mean age at diagnosis was 10.2 +/- 8.5 years (SD, range 0.1-4

85 Median age at diagnosis was 37.2 years; 300 of 509 patients (59

86 16 men and 25 women) were diagnosed: average age at diagnosis was 38.7 years.

87 The mean age at diagnosis was 40.2 years of age for episcleritis

88 Mean age at diagnosis was 54.8 +/- 10.9 y.

89 hundred sixty patients were identified (mean age at diagnosis was 68 years and 49% were females): 122

90 The age at diagnosis was birth to 42 years in men and 2 to 6

91 In these R337H+ cases a lower mean age at diagnosis was observed when compared to the R337H

92 t of smoking), (ii) among women with cancer, age at diagnosis was positively related to 2D:4D, i.e. w

93 The age at diagnosis was similar between the cohorts and nor

94 The mean age at diagnosis was younger for PTC-T (19.8 years vs 28

95 ted hypertrophic cardiomyopathy <18 years of age at diagnosis were eligible.

96 dentified 1699 cases of cardiomyopathy (mean age at diagnosis, 46.2 [SD 9.1] years) during the follow

97 oma cohort included 1295 patients (mean [SD] age at diagnosis, 59.8 [15.6] years; 488 [37.7%] women;

98 e cancer cohort included 1072 men (mean [SD] age at diagnosis, 63.7 [7.9] years; 857 [79.9%] with Eur

99 After adjusting for age at diagnosis, age at questionnaire, emotional distre

100 Risk predictors included age at diagnosis, documented nonsustained ventricular ta

101 erformed using (1) individual INPC criteria (age at diagnosis, histologic category, mitosis-karyorrhe

102 included total number of tumors per patient, age at diagnosis, laterality at presentation and later,

103 Stratification factors were age at diagnosis, planned endocrine therapy, and treatin

104 g colitis (>10 years), male sex, and younger age at diagnosis.

105 ual decline was observed with increasing the age at diagnosis.

106 ve incidence and mortality rate, and average age at diagnosis.

107 = 0.44), suggesting independence between the ages at diagnosis of intraocular retinoblastoma and pine

108 nome-wide genotyping in 145 patients (median age-at-diagnosis of 3.5 years), in whom no Mendelian dis

109 Median age at dialysis initiation was 64 years, 45% were female

110 While it is believed that humans age at different rates, a lack of robust longitudinal hu

111 sceptibility and disease features, including age at disease onset and clinical symptoms.

112 wed significantly stronger associations with age-at-disease-onset, clinical progression, amyloid depo

113 stonia duration in DYT/PARK-TAF1 and younger age at dystonia onset in DYT-SGCE.

114 ated with longer dystonia duration and older age at dystonia onset in DYT-TOR1A, longer dystonia dura

115 cipants of the Penn Medicine Biobank (median age at enrollment 63 years, interquartile range 55-72; 3

116 The median age at enrollment was 3.2 months (interquartile range, 1

117 Among 55,908 participants, the mean age at enrollment was 48.3 years, 26,324 (47.1%) were me

118 cohort of 57,053 individuals 50-64 years of age at enrollment, we identified 21,241 individuals who

119 The mean patient age at entry was 61 years.

120 Excluding WWH with surgical menopause, age at final menstrual period was summarized for postmen

121 Median age at first booking was 25 years (interquartile range [

122 Age at first calving (AFC) plays an important role in th

123 Medical records of 65 patients >50 years of age at first diagnosis of IIH were reviewed based on the

124 We assessed PRS(313) interaction with age at first diagnosis, family history, morphology, ER s

125 s) for GWs, according to vaccination status, age at first dose, and calendar time.

126 found between the two study groups regarding age at first IAC injection, disease grouping at diagnosi

127 ith anti-VEGF agent according to the patient age at first injection ($78 323.19-$292 449.87) and freq

128 ositions based on the agent modeled, patient age at first injection, frequency of injections, and cli

129 The median gestational age at first IPTp-SP dose was 22 weeks.

130 otective effect of pregnancy is dependent on age at first pregnancy, with young mothers receiving the

131 10% of variance in the ratio of fertility to age at first reproduction (F/alpha) and lifetime reprodu

132 erformed survival analysis investigating the age at first SCD in carriers of the mutation.

133 e at vaccination (18.7 years) was older than age at first sex (15.7 years).

134 Age at first TC diagnosis and treatment intensity influe

135 d Main Results: For all 4,240 subjects, mean age at follow up was 65.4 years, 3,486 (82.0%) were male

136 ore inpatient days during childhood, younger age at Fontan surgery, and longer time since Fontan proc

137 Median age at HCT was 1.2 years.

138 We examined the mean age at HCV-associated death, and rates and proportions b

139 r associated with both maternal and paternal age at Holocaust exposure were in the same direction.

140 ent, parental posttraumatic stress disorder, age at Holocaust exposure) and offspring characteristics

141 The median age at hypertension was approximately a decade earlier i

142 The median age at IBD diagnosis was 55 years (range 29-85 years).

143 Age at immigration was categorized into 0 to 5 years of

144 When stratified according to age at immigration, a decrease in myopia prevalence and

145 AF, 21% required de novo pacemakers (median age at implantation 37 years; IQR: 29 to 48 years), 14%

146 ards models (controlling for patient gender, age at index diagnosis of IC, and diagnosis with diabete

147 timated associations by diagnostic criteria, age at infection, and high-risk population.

148 The median age at initial presentation was 72.5 years, and 33.3% we

149 Mean age at initial surgery was 5 months (range, 5 days-48 mo

150 The average age at initial visit was 10.0 months.

151 pact of lipid lowering as a function of age, age at initiation, and non-high-density lipoprotein chol

152 Median age at ITx was 7.7 years and weight was 23 kg.

153 The average age at KC first diagnosis was 29.76 years.

154 lity analyses were restricted to women whose age at last birth (ALB) was >= 30 years, the age when fe

155 g age at menarche, current menstrual status, age at last menstruation, and menopausal aetiology) info

156 nths (range; 5 months-14 years) and the mean age at last visit was 11.3 +/- 6.5 years.

157 Eligibility criteria included age at least 18 years, centrally confirmed triple-negati

158 rials.gov identifier: NCT02953678), patients aged at least 12 years with grades II to IV steroid-refr

159 tes in 26 countries) trial enrolled patients aged at least 18 years with active psoriatic arthritis.

160 ncluded patients with stage III colon cancer aged at least 18 years with an Eastern Cooperative Oncol

161 patients from 49 hospitals in six countries aged at least 18 years with histologically confirmed, ad

162 South Korea, and Republic of Ireland, women (aged at least 18 years) with newly diagnosed, histologic

163 omised trial, patients with advanced cancer, aged at least 18 years, admitted to the palliative and s

164 Patients were aged at least 18 years, with primary or secondary immune

165 ed pregnant women in South Africa and Uganda aged at least 18 years, with untreated but confirmed HIV

166 ICIPANTS: Representative sample of US adults aged at least 40 years in the National Health and Nutrit

167 patients from 29 trials, 21 492 (8.8%) were aged at least 75 years, of whom 11 750 (54.7%) were from

168 f the evaluated clinical outcomes, including age at loss of ambulation (p < 0.001).

169 factors of long-term (beyond 12 mo) CVE were age at LT (hazard ratio [HR], 1.04; 95% confidence inter

170 The age at mammography (mean, 55.7 years vs 54.6 years; P <

171 ciation between puberty timing, particularly age at menarche (AAM), and type 2 diabetes.

172 ide association studies, including those for age at menarche and cardiometabolic traits.

173 x (BMI), smoking, alcohol intake, parity and age at menarche with changes in hormones by reproductive

174 ects of LDL, TGs, body mass index (BMI), and age at menarche, corroborated this observation for HDL (

175 re and adequate menstrual history (including age at menarche, current menstrual status, age at last m

176 od collection for premenopausal women) minus age at menarche, subtracting years of oral contraceptive

177 We estimated LOY as age at menopause (age at blood collection for premenopau

178 Older age at menopause (P = 0.007), earlier menarche (P = 0.00

179 es age of pubertal onset, hormone levels and age at menopause.

180 in myopia prevalence and ORs with increasing age at migration were observed, most prominent in immigr

181 Rates varied depending on age at migration.

182 years (22 years before the estimated median age at mild cognitive impairment onset of 44 years), alt

183 if they had clinical data available on sex, age at motor symptom onset, disease duration (from motor

184 and matched with each case for center, sex, age at MPN diagnosis, date of diagnosis, and MPN disease

185 ht loss >= 5%, tobacco use at LEMS onset and age at onset >= 50 years were independent predictors for

186 testing in Parkinson's disease patients with age at onset < 40 years, especially in those from famili

187 length is the main factor in determining the age at onset (AO) of clinical symptoms.

188 omy was significantly affected by 3 factors: age at onset (HR 1.047, p = 0.006), body mass index < 20

189 the CAG repeat expansion and to the residual age at onset (RAO): The difference between the observed

190 on, whereas 14% (9-22) of the variability of age at onset and 20% (12-30) of that of age at death was

191 group, only 2% (0-10) of the variability of age at onset and 9% (3-21) of that of age of death was e

192 significantly correlated with both parental age at onset and at death and with mean family age at on

193 vestigate the extent to which variability in age at onset and at death could be accounted for by fami

194 e at onset and at death and with mean family age at onset and at death in all three groups, with a st

195 Modelling showed that the variability in age at onset and at death in the MAPT group was explaine

196 We also assessed correlations between the age at onset and at death of each individual and the age

197 t and at death of their parents and the mean age at onset and at death of their family members.

198 nset and at death of each individual and the age at onset and at death of their parents and the mean

199 Individual age at onset and at death was significantly correlated w

200 entia depends on the clinical condition, the age at onset and family history.

201 ase in C9+ individuals (based on the average age at onset of affected relatives in the family).

202 y lower than that of non-carriers, while the age at onset of carriers with other gene pathogenic/like

203 The age at onset of CF-related diabetes (CFRD) (marked by cl

204 DNA variants associated with age at onset of CFRD reside in and near SLC26A9.

205 n in ductal cells of the pancreas delays the age at onset of diabetes, suggesting a CFTR-agnostic tre

206 Mean age at onset of late reactivation was 25.6 years (range,

207 tified that contribute to both LOAD risk and age at onset of LOAD.

208 ies have detected genetic loci modifying the age at onset of motor symptoms in HD, but genetic factor

209 Specifically, the age at onset of Parkinson's disease patients with pathog

210 Furthermore, the age at onset of the 132 probands with genetic diagnoses

211 A dramatic peak in age at onset of vision loss was found among males betwee

212 Although estimation of age at onset will be an important factor in future pre-s

213 xed effects models to explore differences in age at onset, age at death, and disease duration between

214 he GRN group (r=0.22 individual and parental age at onset, r=0.18 individual and mean family age at o

215 at onset, r=0.18 individual and mean family age at onset, r=0.22 individual and parental age at deat

216 9orf72 group (r=0.32 individual and parental age at onset, r=0.36 individual and mean family age at o

217 at onset, r=0.36 individual and mean family age at onset, r=0.38 individual and parental age at deat

218 t, r=0.63 between individual and mean family age at onset, r=0.58 between individual and parental age

219 roup (r=0.45 between individual and parental age at onset, r=0.63 between individual and mean family

220 Male sex, young age at onset, small bowel disease, more active disease,

221 to detect genetic influences on GBA risk and age at onset.

222 he specific mutation (48%, 95% CI 35-62, for age at onset; 61%, 47-73, for age at death), and even mo

223 n more by family membership (66%, 56-75, for age at onset; 74%, 65-82, for age at death).

224 linical practice and research by considering age-at-onset and changes over time as well as different

225 Recent genome-wide association studies of age-at-onset in Huntington's disease (HD) point to disti

226 nock-out of Mlh1, the ortholog of a third HD age-at-onset modifier gene (MLH1), which suppresses soma

227 , we evaluated the mouse orthologs of two HD age-at-onset modifier genes, FAN1 and RRM2B, for an infl

228 ciated with individual-specific variation in age-at-onset not accounted for by ePAL, further highligh

229 A higher PRS was associated with earlier age at PD diagnosis and inclusion of the PRS in the PRED

230 bertal body weight and BMI at 8 y of age and age at peak height velocity (PHV; an objective measure o

231 -0.19, -0.17) were inversely associated with age at PHV but the association for body weight was signi

232 ody weight explained more of the variance in age at PHV than BMI in both the old cohort and the recen

233 In 32 patients identified with ARS (median age at presentation 6.9 years, 0-58.7 years; median foll

234 igated the impact of HBV/HIV co-infection on age at presentation and survival of HCC.

235 The median age at presentation for congenital cataracts that were n

236 The median age at presentation of 35 children was 26 days (interqua

237 emale, with a mean (standard deviation [SD]) age at presentation of 35.2 (14.2) years, and mean refra

238 was 8 years (range, 1-22 years), and median age at presentation of Coats-like exudative vitreoretino

239 Median age at presentation was 2.8 years and median follow-up w

240 Older age at presentation was associated with higher incidence

241 Cox analysis revealed that for PCa patients, age at presentation, older age, single marital status, l

242 Older age at presentation, small bowel disease, serology (anti

243 models, infant vaccination increased average age at primary infection as a result of decreased second

244 ncy, gamete generation, ovulation cycle, and age at puberty.

245 After adjusting for age at diagnosis, age at questionnaire, emotional distress, and cancer tre

246 This measure correlated with age at (r = 0.93) in an independent sample, and related

247 The median age at radical prostatectomy was 62 years.

248 e tested whether song traits were related to age at recording, future survival, longevity, and territ

249 The mean age at RIS diagnosis was 37.2 years (range, 11-74 years)

250 creased over time, driven primarily by ePAL, age-at-sampling and the time interval.

251 length over time not accounted for by ePAL, age-at-sampling and time was inversely associated with i

252 of brain shape and intensity, appropriate to age at scan, degree of prematurity and sex.

253 34 had perinatal HIV infection, and reported age at sexual debut and history of heterosexual vaginal

254 ecific mechanisms underlying primate ovarian aging at single-cell resolution, revealing new diagnosti

255 lationship with duration of progestogen use, age at start and last use, and time since first and last

256 al [CI], 0.09-0.99, P = 0.03) and increasing age at surgery (OR, 0.97, 95% CI, 0.95-0.99, P = 0.02) w

257 and glaucoma or GS correlated strongly with age at surgery (P = 0.011/0.004) and glaucoma correlated

258 vents and glaucoma correlated with a younger age at surgery and glaucoma correlated with the presence

259 Younger age at surgery and smaller (<9.5 mm) corneal diameter at

260 Eighty-seven eyes of 80 patients with a mean age at surgery of 68.9+/-7.03 years were included.

261 Median age at surgery was 12 months (range 1-325 months, mean 7

262 The mean age at surgery was 148 +/- 93 days (range 30-359 days) w

263 The mean age at surgery was 15.0 +/- 9.2 years.

264 The mean age at surgery was 15.94 +/- 27.10 months in the US-Cat

265 Age at surgery was found to be the only clinical variabl

266 Histopathological diagnosis, age at surgery, and duration of epilepsy are important p

267 en histopathology, duration of epilepsy, and age at surgery, and the primary outcomes using random ef

268 were 81% male and 50% nonwhite with a median age at switch of 50 years, CD4+ T-cell count 512 cells/m

269 t for the following variables: variant type, age at symptom onset (AO), and clinical phenotype.

270 Our study showed that age at symptom onset and at death of people with genetic

271 While the mean age at symptom onset was 0.8 +/- 0.6 years [standard dev

272 c studies by doing an international study of age at symptom onset, age at death, and disease duration

273 ospective cohort study, we collected data on age at symptom onset, age at death, and disease duration

274 it may be possible to achieve the biological age at the ground zero lower than that achieved naturall

275 The mean +/- standard deviation age at the index date was 69.0 +/- 1.5 years for all 3 g

276 to autism risk, and correlate with paternal age at the time of conception.

277 StudyPopulation: children <=18 years of age at the time of first claim between 2007 and 2013.

278 The average age at the time of first DSAEK was 70 years (range: 55-8

279 risk for failure was associated with younger age at the time of implantation (<1 year; HR, 27; P = 0.

280 The mean (SD) age at the time of participation in the survey was 43.9

281 mpared with that to timothy extract at all 3 ages: at the age of 4 years, 9.7% versus 6.8%; at the ag

282 lyses were performed on the basis of patient age at time of first injection and frequency interval of

283 Median age at time of RP diagnosis was 8 years (range, 1-22 yea

284 Older age at transition was associated with greater satisfacti

285 Median age at transplant was 21.4 months (0.1-7.8 years).

286 Univariate analysis showed that age at transplantation; steroid use, chronic graft-versu

287 tween host genetics, dose of the at-risk GH, age at treatment onset, and duration of the incubation p

288 gender, ROP treatment method, postmenstrual age at treatment, and coincident nonocular procedures du

289 Median age at vaccination (18.7 years) was older than age at fi

290 This effect was stronger with younger age at vaccination.

291 The positive effect of EBF and age at weaning on gross motor, running and climbing scor

292 of delivery, having siblings, keeping pets, age at weaning, and having had >=4 infections.

293 her age-constant or age-varying FOI, and the age at which 50% and 80% of children had been infected.

294 veloping, whether its onset is linked to the age at which intraocular retinoblastomas develop, and th

295 trations and age, and establish the earliest age at which NfL concentrations begin to diverge between

296 The average age at which people start smoking has been decreasing in

297 es smoked per day and with ex-smokers by the age at which they had quit.

298 perienced no cardiac events until 4 years of age, at which point she was hospitalized because of thre

299 older mothers tended to die before reaching ages at which such senescent decreases could be observed

300 nstrate differences in retinopathy outcomes, age at worst ROP stage, or postnatal growth failure.